These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26264276)

  • 1. Durability of Kinase-Directed Therapies--A Network Perspective on Response and Resistance.
    Murray BW; Miller N
    Mol Cancer Ther; 2015 Sep; 14(9):1975-84. PubMed ID: 26264276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation.
    Trusolino L; Bertotti A
    Cancer Discov; 2012 Oct; 2(10):876-80. PubMed ID: 23071031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.
    Mancini M; Yarden Y
    Semin Cell Dev Biol; 2016 Feb; 50():164-76. PubMed ID: 26428295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacogenomics of drug resistance to protein kinase inhibitors.
    Gillis NK; McLeod HL
    Drug Resist Updat; 2016 Sep; 28():28-42. PubMed ID: 27620953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.
    Lovly CM; Shaw AT
    Clin Cancer Res; 2014 May; 20(9):2249-56. PubMed ID: 24789032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.
    Gutteridge RE; Ndiaye MA; Liu X; Ahmad N
    Mol Cancer Ther; 2016 Jul; 15(7):1427-35. PubMed ID: 27330107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
    Bagrodia S; Smeal T; Abraham RT
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
    Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118635. PubMed ID: 31884070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
    Iams WT; Lovly CM
    Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
    Bagnyukova TV; Serebriiskii IG; Zhou Y; Hopper-Borge EA; Golemis EA; Astsaturov I
    Cancer Biol Ther; 2010 Nov; 10(9):839-53. PubMed ID: 20935499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.
    Cassinelli G; Zuco V; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2013; 20(15):1923-45. PubMed ID: 23410153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment.
    Ghione S; Mabrouk N; Paul C; Bettaieb A; Plenchette S
    Biochem Pharmacol; 2020 Jun; 176():113855. PubMed ID: 32061562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in targeting signal transduction pathways.
    McCubrey JA; Steelman LS; Chappell WH; Sun L; Davis NM; Abrams SL; Franklin RA; Cocco L; Evangelisti C; Chiarini F; Martelli AM; Libra M; Candido S; Ligresti G; Malaponte G; Mazzarino MC; Fagone P; Donia M; Nicoletti F; Polesel J; Talamini R; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Michele M; Tafuri A; Dulińska-Litewka J; Laidler P; D'Assoro AB; Drobot L; Umezawa D; Montalto G; Cervello M; Demidenko ZN
    Oncotarget; 2012 Dec; 3(12):1505-21. PubMed ID: 23455493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular basis of targeting protein kinases in cancer therapeutics.
    Tsai CJ; Nussinov R
    Semin Cancer Biol; 2013 Aug; 23(4):235-42. PubMed ID: 23651790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MKK3 as oncotarget.
    Bossi G
    Aging (Albany NY); 2016 Jan; 8(1):1-2. PubMed ID: 26805700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.